ストックスクリーナーアプリを入手
0.00
100.00%
-5.00
前日終値:
$5.00
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$266.14M
収益：
$44.12M
当期純損益:
$-156.25M
株価収益率:
0.00
EPS:
-3.07
ネットキャッシュフロー:
$-154.61M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$5.30
2 Seventy Bio Inc Stock (TSVT) Company Profile
TSVT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
0.00 | 266.14M | 44.12M | -156.25M | -154.61M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
368.51 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.75 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.82 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
665.19 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.40 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-06 | ダウングレード | Goldman | Neutral → Sell |
| 2024-01-31 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-01-31 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-13 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-05-02 | 開始されました | Goldman | Buy |
| 2022-02-10 | 開始されました | SVB Leerink | Outperform |
| 2022-01-06 | 開始されました | Cowen | Outperform |
| 2021-11-09 | 開始されました | Canaccord Genuity | Buy |
| 2021-11-08 | 開始されました | Morgan Stanley | Overweight |
| 2021-11-08 | 開始されました | Wedbush | Outperform |
すべてを表示
2 Seventy Bio Inc (TSVT) 最新ニュース
Is now a turning point for 2seventy bio Inc.Free Real Trader Watchlist of Hot Stocks - Newser
Real time pattern detection on 2seventy bio Inc. stockLow Risk Stock Selection Strategy Guide - Newser
Analyzing net buyer seller activity in 2seventy bio Inc.Scalable Strategy with Chart Confirmation - Newser
How 2seventy bio Inc. stock performs during market volatilityControlled Entry Strategy With Safety Analytics - Newser
Long term hold vs stop loss in 2seventy bio Inc.Free Safe Entry Stock Watch Suggestions - Newser
Momentum divergence signals in 2seventy bio Inc. chartFree Weekly Hot Picks With Buy Confidence - Newser
Live Scanner Shows Breakout on 2seventy bio Inc.Watchlist for Smart Swing Trading Updated - metal.it
Traders Consider Averaging Down in 2seventy bio Inc.Exit Ready Momentum Stock Watchlist Expanded - beatles.ru
What drives 2seventy bio Inc. stock priceAchieve rapid portfolio growth with expert guidance - Jammu Links News
How does 2seventy bio Inc. compare to its industry peersFree Stock Market Forecast Reports - Jammu Links News
2seventy bio Inc. Stock Analysis and ForecastConsistent double returns - Jammu Links News
What are the technical indicators suggesting about 2seventy bio Inc.Achieve rapid financial growth with expert help - Jammu Links News
What are analysts’ price targets for 2seventy bio Inc. in the next 12 monthsDiscover breakthrough trading strategies - Jammu Links News
How many analysts rate 2seventy bio Inc. as a “Buy”Explosive portfolio gains - Jammu Links News
Should I hold or sell 2seventy bio Inc. stock in 2025Superior trading gains - Jammu Links News
How does 2seventy bio Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What is the dividend policy of 2seventy bio Inc. stockCapitalize on fast-growing investment opportunities - Jammu Links News
What makes 2seventy bio Inc. stock price move sharplyConsistently superior profits - Jammu Links News
Is 2seventy bio Inc. stock overvalued or undervaluedHigh-profit stock alerts - Jammu Links News
Why is 2seventy bio Inc. stock attracting strong analyst attentionUnbelievable profit margins - Jammu Links News
What are the latest earnings results for 2seventy bio Inc.Get expert insights on market-moving stocks - Jammu Links News
When is 2seventy bio Inc. stock expected to show significant growthSpectacular growth rates - Jammu Links News
Is 2seventy bio Inc. Stock a Good Fit for Conservative InvestorsBuy Alerts With Low Risk Confirmation Noted - metal.it
Is 2seventy bio Inc. forming a reversal patternTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Momentum Screeners Rank 2seventy bio Inc. in Top 5 TodayAlpha Driven Watchlist With Alerts Published - metal.it
Heatmap Data Shows High Activity in 2seventy bio Inc. SectorReal Time Alerts Based on AI Prediction Triggered - metal.it
Sector Leaders Rotate Capital Into 2seventy bio Inc.Breakout Confirmation With Entry Tracker Enabled - metal.it
2seventy bio Inc. Company’s Quarterly Earnings Growth: What the Numbers SayAI Powered Stock Call - metal.it
What catalysts could drive 2seventy bio Inc. stock higher in 2025Track emerging stocks with high growth potential - Jammu Links News
How strong is 2seventy bio Inc. company’s balance sheetAchieve consistent double-digit growth - Jammu Links News
Published on: 2025-07-27 15:37:28 - Jammu Links News
Can 2seventy bio Inc. stock recover from recent declineExplosive earning power - Jammu Links News
Why 2seventy bio Inc. stock attracts strong analyst attentionTop Performing Stocks - beatles.ru
Is 2seventy bio Inc. a good long term investmentDynamic investment growth - Jammu Links News
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades - Managed Healthcare Executive
Cigna Launches AI Tools to Simplify Health Insurance, Improve Customer Experience - Managed Healthcare Executive
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC - Managed Healthcare Executive
Alachua bio-manufacturing plant to lay off employees ahead of shutdown - WCJB | TV20
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC - Pharmacy Times
Bonnie Hui-Callahan, Pharm.D., Video Interview | 2025 MHE Emerging Leaders in Healthcare - Managed Healthcare Executive
Wellington Management Group LLP Reduces Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
BNP Paribas Financial Markets Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Deutsche Bank AG Has $1.10 Million Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
MHE Week in Review –Medicaid Bill Mayhem, UnitedHealth’s Stock Plummets and More - Managed Healthcare Executive
Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio Reports Strong Q1 2025 Earnings - TipRanks
Investor relations - Bristol Myers Squibb
Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio completes merger with Bristol-Myers Squibb - Investing.com
2 Seventy Bio Inc (TSVT) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
1.48%
大文字化:
|
ボリューム (24 時間):